

Luana Lionetto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4920063/publications.pdf>

Version: 2024-02-01

81
papers

2,217
citations

218381

26
h-index

253896

43
g-index

82
all docs

82
docs citations

82
times ranked

3500
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>L</sc> -acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4804-4809.	3.3	228
2	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. Journal of Headache and Pain, 2015, 17, 1.	2.5	120
3	Altered intestinal permeability in patients with relapsingâremitting multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2017, 23, 442-446.	1.4	107
4	Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. Scientific Reports, 2016, 5, 17799.	1.6	91
5	Systematic Review of Clozapine Cardiotoxicity. Current Psychiatry Reports, 2016, 18, 68.	2.1	68
6	HPLCâmass spectrometry method for quantitative detection of neuroendocrine tumor markers: Vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. Clinica Chimica Acta, 2008, 398, 53-56.	0.5	65
7	CGRP receptor antagonists: an expanding drug class for acute migraine?. Expert Opinion on Investigational Drugs, 2012, 21, 807-818.	1.9	63
8	Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opinion on Emerging Drugs, 2012, 17, 393-406.	1.0	63
9	Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. Neuropharmacology, 2017, 112, 365-372.	2.0	63
10	OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. SpringerPlus, 2015, 4, 826.	1.2	62
11	Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166042.	1.8	61
12	Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Molecular Brain, 2013, 6, 48.	1.3	59
13	Altered kynurenine pathway metabolites in serum of chronic migraine patients. Journal of Headache and Pain, 2016, 17, 47.	2.5	57
14	A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability. Clinical Biochemistry, 2008, 41, 887-892.	0.8	52
15	Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. Neuropharmacology, 2014, 81, 237-243.	2.0	48
16	Altered serum levels of kynurenine metabolites in patients affected by cluster headache. Journal of Headache and Pain, 2016, 17, 27.	2.5	41
17	Low Prostate Concentration of Lycopene Is Associated with Development of Prostate Cancer in Patients with High-Grade Prostatic Intraepithelial Neoplasia. International Journal of Molecular Sciences, 2014, 15, 1433-1440.	1.8	39
18	Serum Levels of Risperidone and Its Metabolite, 9-Hydroxyrisperidone: Correlation Between Drug Concentration and Clinical Response. Therapeutic Drug Monitoring, 2009, 31, 475-481.	1.0	36

#	ARTICLE	IF	CITATIONS
19	Lasmiditan for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 227-234.	1.9	36
20	Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?. <i>Frontiers in Pharmacology</i> , 2017, 8, 214.	1.6	33
21	A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 482-488.	1.0	31
22	An improved simple LC-MS/MS method for the measurement of serum aripiprazole and its major metabolite. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 62, 135-139.	1.4	30
23	The omics in migraine. <i>Journal of Headache and Pain</i> , 2013, 14, 55.	2.5	30
24	Hedonic sensitivity to natural rewards is affected by prenatal stress in a sex-dependent manner. <i>Addiction Biology</i> , 2016, 21, 1072-1085.	1.4	29
25	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 399-406.	1.5	29
26	Tryptophan and Kynurenine Metabolites: Are They Related to Depression?. <i>Neuropsychobiology</i> , 2019, 77, 23-28.	0.9	29
27	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 414-423.	1.5	28
28	Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2369-2380.	0.9	27
29	Intramuscular Aripiprazole in the Acute Management of Psychomotor Agitation. <i>Pharmacotherapy</i> , 2013, 33, 603-614.	1.2	26
30	Changes in serum levels of kynurenine metabolites in paediatric patients affected by ADHD. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 1433-1441.	2.8	25
31	Urinary concentration of 8-isoprostane as marker of severity of pediatric OSAS. <i>Sleep and Breathing</i> , 2014, 18, 723-729.	0.9	23
32	Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. <i>Internal and Emergency Medicine</i> , 2015, 10, 413-421.	1.0	23
33	Chronic migraine treatment: from OnabotulinumtoxinA onwards. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1217-1227.	1.4	22
34	Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. <i>Oncotarget</i> , 2016, 7, 20612-20620.	0.8	21
35	Maternal exposure to endocrine disruptors and placental transmission: a pilot study. <i>Gynecological Endocrinology</i> , 2018, 34, 1001-1004.	0.7	21
36	Sodium channel antagonists for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1697-1706.	0.9	20

#	ARTICLE	IF	CITATIONS
37	Impairment of left ventricular function early in treatment with clozapine. <i>International Clinical Psychopharmacology</i> , 2015, 30, 282-289.	0.9	20
38	The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. <i>Schizophrenia Bulletin</i> , 2020, 46, 1471-1481.	2.3	20
39	Personalised Healthcare: The DiMA Clinical Model. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 242-252.	0.9	19
40	Profiling lasmiditan as a treatment option for migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 147-153.	0.9	18
41	A Critical Evaluation on MOH Current Treatments. <i>Current Treatment Options in Neurology</i> , 2017, 19, 32.	0.7	17
42	Pharmacokinetic evaluation of frovatriptan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1449-1458.	1.5	16
43	Lenalidomide for aggressive Bâ€cell lymphoma involving the central nervous system?. <i>American Journal of Hematology</i> , 2011, 86, 957-957.	2.0	16
44	Treatment of Perimenstrual Migraine with Triptans: an Update. <i>Current Pain and Headache Reports</i> , 2012, 16, 445-451.	1.3	16
45	Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1043-1050.	1.5	14
46	Development of Asymptomatic Pancreatitis With Paradoxically High Serum Clozapine Levels in a Patient With Schizophrenia and the CYP1A2*1F/1F Genotype. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 737-739.	0.7	13
47	Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 303-305.	0.9	13
48	Fremanezumab for the preventive treatment of migraine in adults. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 741-748.	1.3	13
49	How do you choose the appropriate migraine pharmacotherapy for an elderly person?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1-3.	0.9	13
50	Pharmacogenetic insights into migraine treatment in children. <i>Pharmacogenomics</i> , 2014, 15, 1539-1550.	0.6	12
51	Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 157-164.	0.8	12
52	Pharmacogenetic considerations for migraine therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1-7.	1.5	12
53	The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 1044-1049.	0.7	11
54	High-Performance Liquid Chromatographyâ€Tandem Mass Spectrometry Method for Simultaneous Quantification of Carbamazepine, Oxcarbazepine, and Their Main Metabolites in Human Serum. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 53-58.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?. PLoS ONE, 2016, 11, e0163105.	1.1	10
56	5-Fluorouracil degradation rate could predict toxicity in stages IIâ€“III colorectal cancer patients undergoing adjuvant FOLFOX. Anti-Cancer Drugs, 2017, 28, 322-326.	0.7	10
57	A nomogram to predict 5-fluorouracil toxicity. Anti-Cancer Drugs, 2017, 28, 551-556.	0.7	10
58	Early Life Stress Causes Refractoriness to Haloperidol-Induced Catalepsy. Molecular Pharmacology, 2013, 84, 244-251.	1.0	9
59	Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis. Schizophrenia Research, 2019, 208, 465-466.	1.1	9
60	Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study. Antiviral Therapy, 2011, 16, 879-885.	0.6	8
61	Efficacy and tolerability of almotriptan in menstrual migraine: a comment. Expert Opinion on Pharmacotherapy, 2011, 12, 2279-2281.	0.9	8
62	Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 637-644.	1.5	8
63	5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine. Journal of Oncology Pharmacy Practice, 2020, 26, 1836-1842.	0.5	8
64	Treatment of menstrual migraine: utility of control of related mood disturbances. Expert Review of Neurotherapeutics, 2014, 14, 493-502.	1.4	7
65	The therapeutic potential of novel anti-migraine acute therapies. Expert Opinion on Investigational Drugs, 2015, 24, 141-144.	1.9	7
66	Lacosamide in bipolar disorder: A 30â€“day comparison to a retrospective control group treated with other antiepileptics. Psychiatry and Clinical Neurosciences, 2018, 72, 864-875.	1.0	7
67	Deciphering the task of N-acetyl aspartate in migraine. Expert Review of Neurotherapeutics, 2012, 12, 1057-1059.	1.4	6
68	Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. Oncotarget, 2017, 8, 14050-14057.	0.8	6
69	Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1011-1020.	1.5	5
70	Precise medical decision making in geriatric anti-depressant therapy. Expert Review of Precision Medicine and Drug Development, 2016, 1, 387-396.	0.4	5
71	Urinary and exhaled biomarkers of exerciseâ€“induced bronchoconstriction in atopic asthmatic children. Pediatric Pulmonology, 2019, 54, 1447-1456.	1.0	5
72	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsingâ€“Remitting Multiple Sclerosis Treated With Dimethylfumarate. Frontiers in Neurology, 2021, 12, 683398.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Polyamines serum levels in episodic and chronic migraine. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 249-254.	1.4	4
74	Intestinal permeability in children with recurrent respiratory and gastrointestinal symptoms. <i>Journal of Paediatrics and Child Health</i> , 2015, 51, 1214-1220.	0.4	2
75	Sudden Death Associated with Complex Treatment of Acute Mania: Case Report and Toxicological Findings. <i>Current Psychopharmacology</i> , 2019, 8, 238-243.	0.1	2
76	DHA Oral Supplementation Modulates Serum Epoxydocosapentaenoic Acid (EDP) Levels in Breast Cancer Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-7.	1.9	2
77	Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Journal of Headache and Pain</i> , 2015, 16, A36.	2.5	1
78	OO66. Kynurenine pathway metabolites in cluster headache. <i>Journal of Headache and Pain</i> , 2015, 16, A87.	2.5	1
79	Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths. <i>Addictive Behaviors</i> , 2016, 60, 53-57.	1.7	1
80	Re: Response to Anderson's Letter to the Editor. Comment on: Hemochromatosis and bipolar disorder, Serata et al. (2012) <i>Gen Hosp Psychiatry</i> 34(1)101.e1â€“101.e3. <i>General Hospital Psychiatry</i> , 2012, 34, 433-435.	1.2	0
81	Integrated OMICS tools for personalised medicine. <i>Journal of Headache and Pain</i> , 2015, 16, A9.	2.5	0